Document is current
Any future updates will be listed below
-
Authors
Che, Huiwen https://orcid.org/0000-0002-3651-069X
Jatsenko, Tatjana
Lannoo, Lore https://orcid.org/0000-0002-6271-221X
Stanley, Kate
Dehaspe, Luc
Vancoillie, Leen
Brison, Nathalie
Parijs, Ilse
Van Den Bogaert, Kris
Devriendt, Koenraad https://orcid.org/0000-0002-3651-2548
Severi, Sabien
De Langhe, Ellen https://orcid.org/0000-0002-4045-2146
Vermeire, Severine https://orcid.org/0000-0001-9942-3019
Verstockt, Bram https://orcid.org/0000-0003-3898-7093
Van Calsteren, Kristel
Vermeesch, Joris Robert
-
Funding
Funding for this research was provided by:
Agentschap Innoveren en Ondernemen (HBC.2018.2018)
Katholieke Universiteit Leuven | Universitaire Ziekenhuizen Leuven, KU Leuven (RT 1065)
EU H2020-MSCA-ITN-EJD-MATER
- License Information
-
More Information
Article History
Received: 14 January 2022
Accepted: 21 July 2022
First Online: 14 September 2022
Competing interests
: Patent application pending on ‘Method for analyze cell-free nucleic acids’ (JRV and LD). SV receive research grants from AbbVie, J&J, Galapagos, MSD, Pfizer, and Takeda; speaker fees from AbbVie, Falk, Ferring, Hospira, MSD, Pfizer, Takeda, and Tillotts; consultant for AbbVie, Avaxia, Celgene, Ferring, Galapagos, Genentech/Roche, Gilead, Robarts Clinical Trials, Hospira, Janssen, MSD, Mundipharma, Pfizer, Prodigest, Prometheus, Second Genome, Shire, and Takeda. BV is financially supported for research from Pfizer; lecture fees from AbbVie, Biogen, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, and Truvion; consultancy fees from Applied Strategic, Atheneum, Bristol Myers Squibb, Guidepoint, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, and Takeda.
